Compare Ascendis Pharma A/S (ASND) vs Harley-Davidson Inc (HOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Harley-Davidson Inc — how do they compare? Ascendis Pharma A/S trades at $265.85 (market cap $17.74B), while Harley-Davidson Inc trades at $26 (market cap $2.65B). The key difference: Ascendis Pharma A/S is far larger — about 6.7× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays a 2.92% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | HOG | |
|---|---|---|
Market Cap | $17.74B | $2.65B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $31.03 |
52-Week Low | $163.32 | $17.19 |
Enterprise Value | $18.11B | $3.04B |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Harley-Davidson (HOG) trades at $25.14, up 1.17% today, with a neutral technical outlook and mixed earnings history. The company reported Q1 2026 EPS of $0.22, missing estimates, but Q2 2026 results are due July 23, 2026. Recent news highlights production shifts back to the U.S. and cost-cutting initiatives. Valuation ratios appear attractive with a P/E of 13.03 and P/B of 0.86, though revenue has declined from $5.8B in 2023 to $4.5B in 2025.
The stock faces headwinds from declining revenue and margin pressure, but cost reductions and strategic shifts under new CEO Artie Starrs offer turnaround potential. Analyst consensus is cautious with a $23.20 price target below current levels. Key risks include competitive pressures and execution challenges. The upcoming Q2 earnings will be critical for confirming demand recovery and margin improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →
